A. Alshaikh, Mohammed S Aljamal, Saud Alsifri, A. Alrumaih, S. Bokhari, Mohammed Almuzaini, K. Alyahya, Abdulaziz Bin Shaikh, T. Alharbi, Rashid Aljuwair, Fahad Alsabaan, Emad R. Issak
{"title":"Saudi Consensus for Low-Premixed Insulin Analogues in Type 2 Diabetes: Consensus Report","authors":"A. Alshaikh, Mohammed S Aljamal, Saud Alsifri, A. Alrumaih, S. Bokhari, Mohammed Almuzaini, K. Alyahya, Abdulaziz Bin Shaikh, T. Alharbi, Rashid Aljuwair, Fahad Alsabaan, Emad R. Issak","doi":"10.4236/IJCM.2021.124016","DOIUrl":null,"url":null,"abstract":"We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG in one injection. There are two categories; high-mix and low-mix premixed insulins. We, a Saudi task force, gathered to develop an explicit, evidence-based consensus for the use of the low-mix premixed insulin for better glycemic control. The treatment with premixed aspart 30 was non-inferior to treatment with premixed","PeriodicalId":58771,"journal":{"name":"临床医学国际期刊(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"临床医学国际期刊(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/IJCM.2021.124016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG in one injection. There are two categories; high-mix and low-mix premixed insulins. We, a Saudi task force, gathered to develop an explicit, evidence-based consensus for the use of the low-mix premixed insulin for better glycemic control. The treatment with premixed aspart 30 was non-inferior to treatment with premixed